CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02439138
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:19.613427+00:00
Published At: 2017-01-11T00:00:00+00:00
Record Updated At: 2017-01-11
Results Posted At: 2017-01-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Waldenstrom\u0027s Macroglobulinemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-01-11"
protocolSection.identificationModule.nctId: "NCT02439138"
protocolSection.identificationModule.officialTitle: "Phase II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenstr\u00f6m Macroglobulinemia"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-01-11"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.